Cohance Lifesciences LtdQ4 FY24
Cohance Lifesciences Ltd Q4 FY24 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Price: ₹442P/E: 82.0Market Cap: ₹16.2K CrSector: Pharmaceuticals & Biotechnology
Revenue guidance
No information is provided regarding the same in the latest conference call.
Margin guidance
No information is provided regarding the same in the latest conference call.
3 more insights locked — sign up free to unlock
Fundraise plans
No information is provided regarding the same in the latest conference call.
Order book
No information is provided regarding the same in the latest conference call.
Capex plans
No information is provided regarding the same in the latest conference call.
How does Cohance Lifesciences Ltd rank vs peers in Pharmaceuticals & Biotechnology?
Pro feature1Cohance Lifesciences Ltd
See full Pharmaceuticals & Biotechnology sector rankings